XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue:    
Total revenue $ 1,826 $ 1,694
Operating costs and expenses:    
Cost of license revenue and products sold 651 1,348
Research and development 92,861 107,649
Selling, general and administrative 31,108 43,713
Restructuring, impairment and related charges 3,369 22,662
Total operating costs and expenses 127,989 175,372
Loss from operations (126,163) (173,678)
Other income (expense), net:    
Interest income 4,153 267
Interest expense (20,121) (20,344)
Other expense, net (601) (7,575)
Total other income (expense), net (16,569) (27,652)
Net loss (142,732) (201,330)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests 2,576 4,933
Net loss attributable to common stockholders of BridgeBio $ (140,156) $ (196,397)
Net loss per share attributable to common stockholders of BridgeBio, basic $ (0.92) $ (1.35)
Net loss per share attributable to common stockholders of BridgeBio, diluted $ (0.92) $ (1.35)
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic 152,645,635 145,882,149
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted 152,645,635 145,882,149
License and Services Revenue    
Revenue:    
Total revenue $ 1,826 $ 235
Product Sales    
Revenue:    
Total revenue   $ 1,459